Research programme: coronavirus vaccines - Novavax

Drug Profile

Research programme: coronavirus vaccines - Novavax

Alternative Names: MERS vaccine - Novavax; Middle East Respiratory Syndrome Coronavirus (MERS-CoV) vaccine - Novavax

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novavax
  • Class Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Middle East respiratory syndrome coronavirus
  • Discontinued Severe acute respiratory syndrome

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Middle-East-respiratory-syndrome-coronavirus(Prevention) in USA
  • 30 Apr 2014 Final immunogenicity data from a preclinical trial in Middle East respiratory syndrome (MERS-CoV) and Severe acute respiratory syndrome (SARS) coronavirus infections released by Novavax
  • 06 Jun 2013 Preclinical trials in prevention of Coronavirus (Middle East Respiratory Syndrome) infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top